RxDoctor Payments Data

Scott Wehrly, MD

Ophthalmology · Tavares, FLNPI 1174563696

Payments from drug & device makers

$12,744in general payments, 2019–2025

Across 232 payments — averaging $54.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$8K
  • AbbVie$1K
  • Alcon$829
  • Ocular Therapeutix, Inc.$750
  • Glaukos Corporation$395
  • Nova Eye, Inc.$296
  • plus $893 from 12 others

What the payments were for

  • Consulting fees$3,13225%
  • Speaking & faculty fees$4,03232%
  • Travel & lodging$3543%
  • Food & beverage$4,92939%
  • Entertainment$2962%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,744 in reported general payments places this provider in the 80th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$691,712
Medicare patients
1,633
Services billed
4,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine38$43,698
LumiganBimatoprost48$31,431
Prednisolone Acetate337$13,773
Cyclosporine21$11,510
RocklatanNetarsudil Mesylat/Latanoprost23$8,688
Fluorometholone70$6,597
Latanoprost306$3,885
SimbrinzaBrinzolamide/Brimonidine Tart11$2,964
Tobramycin-DexamethasoneTobramycin/Dexamethasone41$2,113
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat76$1,666
Timolol Maleate76$1,531
MoxifloxacinMoxifloxacin Hcl42$1,093
Ketorolac Tromethamine23$1,010
Pilocarpine Hcl12$637
Brimonidine Tartrate51$597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$1,269$75,12986 claims
Aerie Pharmaceuticals, Inc.Rocklatan$108$8,68823 claims
AlconSimbrinza$829$2,96411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Tavares

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →